Emcure Pharmaceuticals submitted it's Draft Red Hearing Prospectus (DRHP) for its proposed initial public offering with market regulator Securities and Exchange Board of India (SEBI) on August 19. (IPO).
Emcure Pharmaceuticals Limited, one of India's biggest pharmaceutical businesses, has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds through an IPO (IPO).
The offer included a fresh issue of up to Rs 1,100 crores in shares and an offer for sale of up to 18,168,356 shares. Promoters and Bain Capital, a private equity firm, are among those who will sell their stock. A pre-IPO placement of up to Rs 200 crore is being considered by the corporation. The size of the new issue will be reduced if this placement is accomplished. The proceeds of the new offering will be used to pay down debt and for other company reasons.
The company intends to use the net proceeds from the new issuance to repay all or a portion of its debt, as well as for general corporate reasons.
The company had a profit of Rs 418.59 crore on revenue of Rs 6091.80 crore in fiscal 2021. In FY20, the profit was Rs 100.61 crore, while in FY19, it was Rs 202.96 crore.
Emcure claims to be an R&D-driven firm with a differentiated product portfolio that includes orals, injectables, and biologics, as well as an mRNA platform via which it is currently developing a COVID-19 vaccine, allowing it to reach a wide range of target markets in over 70 countries.
The Global Co-Ordinators and Book Running Lead Managers for the issuance are Axis Capital, BofA Securities India, Credit Suisse Securities, JM Financial NSE -2.59 percent, and BOB Capital Markets.